Cornell, R., Hari, P., Tang, S., Biran, N., Callander, N., Chari, A., … Costa, L. (2021). Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol, 96(1), E5–E8. https://doi.org/10.1002/ajh.26010

Cornell, Robert, Parameswaran Hari, Shijie Tang, Noa Biran, Natalie Callander, Ajai Chari, Saurabh Chhabra, et al. “Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.” Am J Hematol 96, no. 1 (January 2021): E5–8. https://doi.org/10.1002/ajh.26010.

Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, et al. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021 Jan;96(1):E5–8.

Cornell, Robert, et al. “Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.” Am J Hematol, vol. 96, no. 1, Jan. 2021, pp. E5–8. Pubmed, doi:10.1002/ajh.26010.

Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021 Jan;96(1):E5–E8.